Stem cell-based approaches to treating HIV infection

Current Opinion in HIV and AIDS

Volumn 6, Issue 1, 2011, Pages 68-73

  Kitchen, Scott G ^a   Zack, Jerome A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Engineered immunity; Gene therapy; HIV therapy; Stem cells

Indexed keywords

ARTICLE; CELL PROTECTION; GENE THERAPY; HEMATOPOIETIC CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; LEUKOCYTE; PRIORITY JOURNAL; STEM CELL; STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; INNATE IMMUNITY; PHYSIOLOGY; REVIEW; VIROLOGY;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HIV INFECTIONS; HUMANS; IMMUNITY, INNATE;

EID: 79954434834     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283412370     Document Type: Article

References (71)

1. Rossi JJ, June CH, Kohn DB. Genetic therapies against HIV. Nat Biotechnol 2007; 25:1444-1454. (Pubitemid 350233141)
2. Shimizu S, Hong P, Arumugam B, et al. A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood 2010; 115:1534-1544.
3. Holt N, Wang J, Kim K, et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010; 28:839-847.
4. Mitsuyasu R, Merigan TC, Carr A, et al. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med 2009; 15:285-292.
5. DiGiusto DL, Krishnan A, Li L, et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34+ cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2010; 2:36ra43.
6. Kitchen SG, Bennett M, Galic Z, et al. Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice. PLoS One 2009; 4:e8208.
7. Gratwohl A, Baldomero H, Aljurf M, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA 2010; 303:1617-1624.
8. Brenchley JM, Silvestri G, Douek DC. Nonprogressive and progressive primate immunodeficiency lentivirus infections. Immunity 2010; 32:737-742.
9. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010; 464:217-223.
10. Ahlers JD, Belyakov IM. Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS. Trends Immunol 2010. [Epub ahead of print].
11. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009; 206:1253-1272.
12. Streeck H, Jolin JS, Qi Y, et al. Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J Virol 2009; 83:7641-7648.
13. Li Q, Skinner PJ, Ha SJ, et al. Visualizing antigen-specific and infected cells in situ predicts outcomes in early viral infection. Science 2009; 323:1726-1729.
14. Goulder PJ, Watkins DI. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol 2008; 8:619-630.
15. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8:247-258. (Pubitemid 351432801)
16. Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. Cell 2009; 138:30-50.
17. Kelley CF, Kitchen CM, Hunt PW, et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis 2009; 48:787-794.
18. Battegay M, Nuesch R, Hirschel B, Kaufmann GR. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis 2006; 6:280-287.
19. Muller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:251-261.
20. Antonelli LR, Mahnke Y, Hodge JN, et al. Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome. Blood. [Epub ahead of print]
21. Maddon PJ, Littman DR, Godfrey M, et al. The isolation and nucleotide sequence of a cDNA encoding the T cell surface protein T4: a new member of the immunoglobulin gene family. Cell 1985; 42:93-104. (Pubitemid 16237560)
22. Brenchley JM, Hill BJ, Ambrozak DR, et al. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol 2004; 78:1160-1168. (Pubitemid 38095826)
23. Kitchen SG, Jones NR, LaForge S, et al. CD4 on CD8+ T cells directly enhances effector function and is a target for HIV infection. Proc Natl Acad Sci U S A 2004; 101:8727-8732. (Pubitemid 38745839)
24. Carter CC, Onafuwa-Nuga A, McNamara LA, et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med 2010; 16:446-451.
25. Louache F, Debili N, Marandin A, et al. Expression of CD4 by human hematopoietic progenitors. Blood 1994; 84:3344-3355. (Pubitemid 24352896)
26. Muench MO, Roncarolo MG, Namikawa R. Phenotypic and functional evidence for the expression of CD4 by hematopoietic stem cells isolated from human fetal liver. Blood 1997; 89:1364-1375. (Pubitemid 27080001)
27. Moir S, Lapointe R, Malaspina A, et al. CD40-mediated induction of CD4 and CXCR4 on B lymphocytes correlates with restricted susceptibility to human immunodeficiency virus type 1 infection: potential role of B lymphocytes as a viral reservoir. J Virol 1999; 73:7972-7980. (Pubitemid 29441655)
28. Valentin A, Rosati M, Patenaude DJ, et al. Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc Natl Acad Sci U S A 2002; 99:7015-7020. (Pubitemid 34526249)
29. Bernstein HB, Plasterer MC, Schiff SE, et al. CD4 expression on activated NK cells: ligation of CD4 induces cytokine expression and cell migration. J Immunol 2006; 177:3669-3676. (Pubitemid 44359898)
30. Lucey DR, Dorsky DI, Nicholson-Weller A, Weller PF. Human eosinophils express CD4 protein and bind human immunodeficiency virus 1 gp120. J Exp Med 1989; 169:327-332. (Pubitemid 19035564)
31. Filion LG, Izaguirre CA, Garber GE, et al. Detection of surface and cytoplasmic CD4 on blood monocytes from normal and HIV-1 infected individuals. J Immunol Methods 1990; 135:59-69.
32. Biswas P, Mantelli B, Sica A, et al. Expression of CD4 on human peripheral blood neutrophils. Blood 2003; 101:4452-4456. (Pubitemid 36857813)
33. Li Y, Li L, Wadley R, et al. Mast cells/basophils in the peripheral blood of allergic individuals who are HIV-1 susceptible due to their surface expression of CD4 and the chemokine receptors CCR3, CCR5, and CXCR4. Blood 2001; 97:3484-3490.
34. O'Doherty U, Steinman RM, Peng M, et al. Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium. J Exp Med 1993; 178:1067-1076.
35. Jordan CA, Watkins BA, Kufta C, Dubois-Dalcq M. Infection of brain microglial cells by human immunodeficiency virus type 1 is CD4 dependent. J Virol 1991; 65:736-742.
36. Asparuhova MB, Barde I, Trono D, et al. Development and characterization of a triple combination gene therapy vector inhibiting HIV-1 multiplication. J Gene Med 2008; 10:1059-1070.
37. Hammer D, Wild J, Ludwig C, et al. Fusion of Epstein-Barr virus nuclear antigen-1-derived glycine-alanine repeat to trans-dominant HIV-1 Gag increases inhibitory activities and survival of transduced cells in vivo. Hum Gene Ther 2008; 19:622-634. (Pubitemid 351913524)
38. Shimizu S, Kamata M, Kittipongdaja P, et al. Characterization of a potent noncytotoxic shRNA directed to the HIV-1 co-receptor CCR5. Genet Vaccines Ther 2009; 7:8.
39. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273:1856-1862.
40. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996; 2:1240-1243. (Pubitemid 26375409)
41. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722-725.
42. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360:692-698.
43. Alkhatib G. The biology of CCR5 and CXCR4. Curr Opin HIV AIDS 2009; 4:96-103.
44. Kuipers H, Workman C, Dyer W, et al. An HIV-1-infected individual homozygous for the CCR-5 delta32 allele and the SDF-1 30A allele. AIDS 1999; 13:433-434. (Pubitemid 29095115)
45. Gorry PR, Zhang C, Wu S, et al. Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5 Delta 32 allele. Lancet 2002; 359:1832-1834. (Pubitemid 34607062)
46. Biti R, Ffrench R, Young J, et al. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat Med 1997; 3:252-253. (Pubitemid 27112898)
47. Balotta C, Bagnarelli P, Violin M, et al. Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS 1997; 11:F67-F71. (Pubitemid 27298084)
48. O'Brien TR, Winkler C, Dean M, et al. HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet 1997; 349:1219. (Pubitemid 27190047)
49. Theodorou I, Meyer L, Magierowska M, et al. HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group. Lancet 1997; 349:1219-1220.
50. Sheppard HW, Celum C, Michael NL, et al. HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion. J Acquir Immune Defic Syndr 2002; 29:307-313. (Pubitemid 34208541)
51. Michael NL, Nelson JA, KewalRamani VN, et al. Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. J Virol 1998; 72:6040-6047. (Pubitemid 28283393)
52. Naif HM, Cunningham AL, Alali M, et al. A human immunodeficiency virus type 1 isolate from an infected person homozygous for CCR5Delta32 exhibits dual tropism by infecting macrophages and MT2 cells via CXCR4. J Virol 2002; 76:3114-3124. (Pubitemid 34224513)
53. Oh DY, Jessen H, Kucherer C, et al. CCR5Delta32 genotypes in a German HIV-1 seroconverter cohort and report of HIV-1 infection in a CCR5Delta32 homozygous individual. PLoS One 2008; 3:e2747.
54. Varela-Rohena A,Molloy PE, Dunn SM, et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med 2008; 14:1390-1395.
55. Joseph A, Zheng JH, Follenzi A, et al. Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity. J Virol 2008; 82:3078-3089. (Pubitemid 351329196)
56. Miles JJ, Silins SL, Burrows SR. Engineered T cell receptors and their potential in molecular medicine. Curr Med Chem 2006; 13:2725-2736. (Pubitemid 44509720)
57. Cooper LJ, Kalos M, Lewinsohn DA, et al. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J Virol 2000; 74:8207-8212. (Pubitemid 30641669)
58. Luo XM, Maarschalk E, O'Connell RM, et al. Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes. Blood 2009; 113:1422-1431.
59. Joseph A, Zheng JH, Chen K, et al. Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody. J Virol 2010; 84:6645-6653.
60. Roberts MR, Qin L, Zhang D, et al. Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood 1994; 84:2878-2889. (Pubitemid 24328074)
61. Yang OO, Tran AC, Kalams SA, et al. Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells. Proc Natl Acad Sci U S A 1997; 94:11478-11483. (Pubitemid 27451024)
62. Timmermans F, Velghe I, Vanwalleghem L, et al. Generation of T cells from human embryonic stem cell-derived hematopoietic zones. J Immunol 2009; 182:6879-6888.
63. Galic Z, Kitchen SG, Kacena A, et al. T lineage differentiation from human embryonic stem cells. Proc Natl Acad Sci U S A 2006; 103:11742-11747. (Pubitemid 44182521)
64. Galic Z, Kitchen SG, Subramanian A, et al. Generation of T lineage cells from human embryonic stem cells in a feeder free system. Stem Cells 2009; 27:100-107.
65. Bandi S, Akkina R. Human embryonic stem cell (hES) derived dendritic cells are functionally normal and are susceptible to HIV-1 infection. AIDS Res Ther 2008; 5:1.
66. Subramanian A, Guo B, Marsden MD, et al. Macrophage differentiation from embryoid bodies derived from human embryonic stem cells. J Stem Cells 2009; 4:29-45.
67. Anderson JS, Bandi S, Kaufman DS, Akkina R. Derivation of normal macrophages from human embryonic stem (hES) cells for applications in HIV gene therapy. Retrovirology 2006; 3:24.
68. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861-872. (Pubitemid 350138099)
69. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318:1917-1920.
70. Park IH, Zhao R, West JA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008; 451:141-146.
71. Lowry WE, Richter L, Yachechko R, et al. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci U S A 2008; 105:2883-2888. (Pubitemid 351723638)